<DOC>
	<DOCNO>NCT02674984</DOCNO>
	<brief_summary>This study evaluate safety tolerability combination probiotic BB-12 LGG healthy child autism spectrum disorder age 6-13 year . Subjects randomize BB-12 LGG orally ( LGG dose : 10^9 c.f.u . 's ; BB-12 : 10^9 ) total 28 dos placebo ( maltodextrin ) 2:1 ratio . The time study treatment 28 day , target sample size 45 individual ( i.e. , 30 treatment arm 15 placebo arm ) .</brief_summary>
	<brief_title>Road Discovery Combination Probiotic BB-12 With LGG Treating Autism Spectrum Disorder</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<criteria>Healthy child autism spectrum disorder ( 6 13 year old ) gastrointestinal symptom recognize illness enrol study . There selection basis age , race , gender . Pregnancy breastfeed Subjects take immunosuppressive medication , include oral corticosteroid A history positive result HIV , Hepatitis B , and/or Hepatitis C test Abnormal lab test result ( Section 5.2 ) Gastrointestinal diseases celiac disease , inflammatory bowel disease Subjects allergy antibiotic Presence fever preexist adverse event monitor study Use probiotic last 90 day Acute diarrheal illness within past 30 day Recent ( within 2 week ) current use oral antibiotic /antifungals Current use oral laxative Subjects implant prosthetic device include prosthetic heart valves We require subject take probioticcontaining product , include yogurt supplement probiotic study period .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>